 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
|
|
| |
| Company Profile |
| |
|
NeoRx Corporation, a biotechnology company, engages in the development and commercialization of cancer therapy products. The company focuses on development of Picoplatin (NX473), a platinum compound, designed to improve efficacy of existing platinum therapeutics for cancer. Picoplatin, which is in phase II clinical trial stage, is used in solid tumor cancers, including lung cancer and colorectal cancer. NeoRx was formed in 1984 and is headquartered in Seattle, Washington.
|
NEORX CP Related |
|
NERX - Neorx Cp - Stock Analysis - 9th of November 2008 Stock analysis for Neorx Cp - traded on the NDC using the symbol NERX - with information on the Main Industry category as of 9th of November 2008
|
|
Open Positions on Short Sales Decrease by 5% on Nasdaq - New York Times Adelphia Commun Cp A. 138,514. 114,814. Adia Services Inc ... Neorx Cp* T. 46,372. 181,470. Nestor Inc. 31,900. 45,790. Network General Cp T. 654,757. 807,727 ...
|
|
Open Positions on Short Sales Surge 8.99% on the Nasdaq - New York Times A S K Cp. 113,954. 155,363. A S T Research Inc T. 769,875. 1, ... Neorx Cp T. 314,080. 140,972. Network General Cp T. 87,061. 44,059. Neutrogena Cp T. 483,563 ...
|
|
|
|
|
